Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile Dysfunction
- 9 November 2004
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (19), 3149-3155
- https://doi.org/10.1161/01.cir.0000146906.42375.d3
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Editorial BoardThe American Journal of Cardiology, 2003
- Erectile Dysfunction in the Cardiac Patient: How Common and Should We Treat?Journal of Urology, 2003
- Overview of the cardiovascular effects of tadalafilEuropean Heart Journal Supplements, 2002
- Prevalence of erectile dysfunction: need for treatment?International Journal Of Impotence Research, 2002
- Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medicationJournal Of Hypertension, 2000
- Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panelThe American Journal of Cardiology, 2000
- Erectile Dysfunction and Coronary Risk Factors: Prospective Results from the Massachusetts Male Aging StudyPreventive Medicine, 2000
- DiscussionThe American Journal of Cardiology, 1999
- Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunctionInternational Journal Of Impotence Research, 1998
- Study of Etiologic Relationship of Arterial Atherosclerosis to Corporal Veno-Occlusive Dysfunction in the RabbitJournal of Urology, 1996